Almac Group Further Expands Global Analytical Services Capability
April 15, 2019
Craigavon, N.I., 15 April 2019 – Further to Almac Group’s recent announcement regarding expansion of its global analytical services capabilities, the organisation is delighted to announce additional expansion plans at its Athlone facility.
Currently employing over 150 highly skilled analysts working in GMP / GLP environments from its 3 locations in Craigavon, UK; Athlone, Ireland; and Souderton, Pennsylvania, North America, Almac is positioned as the partner of choice with significant experience in a wide range of analytical services.
In October, Almac’s Sciences Business Unit united its world-class capabilities to form a global analytical group to meet the varying requirements of its clients’ development programs.
As a result of ongoing and increased demand, Almac is now investing significantly in additional laboratory space at its Athlone facility in order to support microbiology and GMP analysis of small and large molecules.
As a result of this expansion, the company will seek to double its existing workforce with up to 40 highly skilled new jobs being created in the next 24 months.
Dr John Robson, Vice President Quality Operations at Almac Sciences, commented:
“When we acquired the Athlone facility in 2017 we recognised a clear potential to expand and develop the highly experienced team to complement our analytical services at our global headquarter campus and facility in the US. Almac is committed to offering a best-in-class service to our global client base and delighted to continue at pace with significant investment across all our facilities in order to strengthen our competitive position in the marketplace.”
Find out more about Almac’s range of analytical services here.
About Almac Group
‘Partnering to Advance Human Health’
The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.
The international company is a privately-owned organisation that has organically grown over 50 years and now employs over 5600 highly skilled personnel.
Almac is headquartered in Craigavon, Northern Ireland with 17 operations across Europe, the US (Pennsylvania, North Carolina and California) and Asia (Singapore and Tokyo).